205 related articles for article (PubMed ID: 11344389)
1. Distribution and functional significance of somatostatin receptors in malignant melanoma.
Lum SS; Fletcher WS; O'Dorisio MS; Nance RW; Pommier RF; Caprara M
World J Surg; 2001 Apr; 25(4):407-12. PubMed ID: 11344389
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Rostomily RC; Elias M; Deng M; Elias P; Born DE; Muballe D; Silbergeld DL; Futran N; Weymuller EA; Mankoff DA; Eary J
Head Neck; 2006 Apr; 28(4):305-12. PubMed ID: 16470879
[TBL] [Abstract][Full Text] [Related]
3. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
4. The current status of somatostatin receptors in malignant melanoma.
Fletcher WS; Lum SS; Nance RW; Pommier RF; O'Dorisio MS
Yale J Biol Med; 1997; 70(5-6):561-3. PubMed ID: 9825484
[TBL] [Abstract][Full Text] [Related]
5. The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
Wang F; Wang Z; Wu J; Qu W; Yao W; Zhao J; Liu Z
Nucl Med Biol; 2008 Aug; 35(6):665-71. PubMed ID: 18678351
[TBL] [Abstract][Full Text] [Related]
6. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.
Casarini AP; Jallad RS; Pinto EM; Soares IC; Nonogaki S; Giannella-Neto D; Musolino NR; Alves VA; Bronstein MD
Pituitary; 2009; 12(4):297-303. PubMed ID: 19330452
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor expression in non-classical locations - clinical relevance?
Bhanat E; Koch CA; Parmar R; Garla V; Vijayakumar V
Rev Endocr Metab Disord; 2018 Jun; 19(2):123-132. PubMed ID: 30324319
[TBL] [Abstract][Full Text] [Related]
12. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
13. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptors and disease: role of receptor subtypes.
Hofland LJ; Lamberts SW
Baillieres Clin Endocrinol Metab; 1996 Jan; 10(1):163-76. PubMed ID: 8734455
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.
Muscarella LA; D'Alessandro V; la Torre A; Copetti M; De Cata A; Parrella P; Sperandeo M; Pellegrini F; Frusciante V; Maiello E; Merla G; Fazio VM; Vendemiale G
Cell Oncol (Dordr); 2011 Oct; 34(5):435-41. PubMed ID: 21503779
[TBL] [Abstract][Full Text] [Related]
16. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours.
Hashemi SH; Benjegård SA; Ahlman H; Wängberg B; Forssell-Aronsson E; Billig H; Nilsson O
Br J Surg; 2003 May; 90(5):549-54. PubMed ID: 12734860
[TBL] [Abstract][Full Text] [Related]
17. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]